| News
Van Baerle to benefit from Schweizerhalle location
13.11.2018
Next year, chemical company Van Baerle will move from Münchenstein in the canton of Basellandschaft to the Schweizerhalle industrial location. Owner and CEO Daniel Schenk summarized the advantages of the new location in an interview.

Lager Hygieneprodukte, Standort Münchenstein (img. van Baerle)
Van Baerle is leaving Münchenstein after some 130 years because the site is too large for the company, explained Daniel Schenk in an interview. “We have over 20,000 square metres here, while at the new location it will still be around 10,000 square metres.”
But that is not the only reason for staying in the Basel region. Van Baerle is relocating to the chemical and pharmaceutical cluster in Schweizerhalle in the immediate vicinity of companies such as Novartis. Although this proximity was not the decisive factor in favour of the new location, Van Baerle is still set to benefit from it. “We need alkalis for our production – and these are produced in Schweizerhalle,” said Schenk. “We will also be able to exploit synergies in supply with water and steam as well as wastewater.”
The Basel economic development agency proposed the new location to Van Baerle.
For Van Baerle, relocating abroad would not have generated enough advantages. Schenk cited the “solid economic reasons that speak in favour of Switzerland as a business location”. He said that the legal framework in Switzerland enables flexibility and entrepreneurial action and named training and the labour market as other arguments in favour of Switzerland.
Schenk also said that he cannot imagine a Switzerland without industrial activities: “This might be possible for very small countries such as Monaco or Liechtenstein, but not for Switzerland. We have to take care of our workplace.” He added that Swissness will still play a role internationally, even if production costs are lower abroad.
Particularly in the Basel region, the planned reduction in the corporate tax rate is also attractive for the company, even if the privileges of a holding company no longer exist. “The bottom line is that Van Baerle will benefit”, concluded Schenk.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...
Read MoreRecord figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...
Read MoreNoema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....
Read MoreWhy CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...
Read MoreBasel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...
Read MoreAriceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...
Read MoreRocketVax raises fresh capital
The Basel-based biotech startup RocketVax has successfully closed another financing round. This additional funding will primarily be used to further...
Read MoreClinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read More